Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,000 | $36.75 | $294,000.00 |
DisclosureSEC source: 0001225208-23-011074 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,502.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-010210 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 6,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,700 | $65.66 | $242,929.05 |
DisclosureSEC source: 0001225208-23-010210 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.28 to $66.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,300 | $64.72 | $148,851.17 |
DisclosureSEC source: 0001225208-23-010210 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,202.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.28 to $65.21. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,000 | $36.75 | $220,500.00 |
DisclosureSEC source: 0001225208-23-010210 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,502.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-009478 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $70.25 | $210,753.60 |
DisclosureSEC source: 0001225208-23-009478 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.05 to $70.45. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,000 | $69.58 | $139,155.60 |
DisclosureSEC source: 0001225208-23-009478 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.05 to $69.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,000 | $36.75 | $183,750.00 |
DisclosureSEC source: 0001225208-23-009478 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,502.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008937 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 4,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,500 | $73.71 | $331,695.00 |
DisclosureSEC source: 0001225208-23-008937 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,500 | $36.75 | $165,375.00 |
DisclosureSEC source: 0001225208-23-008937 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,002.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008220 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 4,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,500 | $79.30 | $356,850.00 |
DisclosureSEC source: 0001225208-23-008220 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,500 | $36.75 | $165,375.00 |
DisclosureSEC source: 0001225208-23-008220 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,002.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-007512 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 3,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,500 | $92.94 | $325,275.30 |
DisclosureSEC source: 0001225208-23-007512 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.68 to $93.26 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,500 | $36.75 | $128,625.00 |
DisclosureSEC source: 0001225208-23-007512 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,002.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-006824 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 3,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,500 | $89.77 | $314,195.00 |
DisclosureSEC source: 0001225208-23-006824 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,502.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,500 | $36.75 | $128,625.00 |
DisclosureSEC source: 0001225208-23-006824 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,002.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 8,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,025 Underlying: Common Stock · 8,025 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 54,200 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · derivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,200 Underlying: Common Stock · 54,200 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 6,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,502.6931 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 2,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $89.22 | $223,050.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,077.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $36.75 | $91,875.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,577.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,399 | $88.74 | $124,147.26 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,624.6931 Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 4,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 4,767 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,968 | $88.74 | $263,380.32 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,023.6931 Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,991.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 05, 2023 Filed May 9, 2023 01:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,635 | $88.63 | $499,401.88 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,224.6931 Read SEC document |
| May 04, 2023 Filed May 5, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 496 | $88.10 | $43,697.60 |
DisclosureSEC source: 0001225208-23-005430 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,859.6931 Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005430 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 111,605 F1 · kind: Bona fide gift. Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 468 | $87.81 | $41,095.08 |
DisclosureSEC source: 0001225208-23-005430 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,355.6931 Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,725 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-004762 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,725 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,725 | $83.09 | $558,801.10 |
DisclosureSEC source: 0001225208-23-004762 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,823.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.80 to $83.45 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,725 | $35.20 | $236,697.81 |
DisclosureSEC source: 0001225208-23-004762 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,548.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| March 08, 2023 Filed Mar 8, 2023 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,725 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-003596 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 Underlying: Common Stock · 6,725 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2023 Filed Mar 8, 2023 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,725 | $76.96 | $517,558.02 |
DisclosureSEC source: 0001225208-23-003596 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560.7842 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.40 to $77.37 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2023 Filed Mar 8, 2023 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,725 | $35.20 | $236,697.81 |
DisclosureSEC source: 0001225208-23-003596 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,285.7842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,725 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-001375 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,450 Underlying: Common Stock · 6,725 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,725 | $80.75 | $543,043.75 |
DisclosureSEC source: 0001225208-23-001375 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560.7842 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 01:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,725 | $35.20 | $236,697.81 |
DisclosureSEC source: 0001225208-23-001375 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,285.7842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| January 09, 2023 Filed Jan 9, 2023 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,725 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-000521 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,175 Underlying: Common Stock · 6,725 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2023 Filed Jan 9, 2023 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,725 | $77.50 | $521,187.50 |
DisclosureSEC source: 0001225208-23-000521 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560.7842 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| January 09, 2023 Filed Jan 9, 2023 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,725 | $35.20 | $236,697.81 |
DisclosureSEC source: 0001225208-23-000521 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,285.7842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| December 12, 2022 Filed Dec 12, 2022 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,725 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-012578 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 6,725 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 12, 2022 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,725 | $74.32 | $499,802.00 |
DisclosureSEC source: 0001225208-22-012578 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560.7842 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
| December 12, 2022 Filed Dec 12, 2022 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,725 | $35.20 | $236,697.81 |
DisclosureSEC source: 0001225208-22-012578 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,285.7842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.